<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7026129/results/search/drugs/results.xml">
  <result pre="or newly discovered agents in vitro and in vivo, with" exact="ribavirin" post="and favipiravir being the most promising candidates. While animal"/>
  <result pre="the limited efficacy of ribavirin, it was also speculated that" exact="ribavirin" post="would be effective in patients with a viral load"/>
  <result pre="load &amp;lt;1 × 106 copies/mL. Favipiravir showed higher efficacy than" exact="ribavirin" post="against SFTSV in in vitro assays and greater efficacy"/>
  <result pre="with thrombocytopenia syndrome severe fever with thrombocytopenia syndrome virus antiviral" exact="ribavirin" post="favipiravir Funding Ministry of Health, Labour and Welfare10.13039/501100003478H25-Shinko-Shitei-009 Japan"/>
  <result pre="U/mL IFNγ IC90 = 12 ng/ml &amp;gt;2,000 ng/mL *Combination with" exact="ribavirin" post="and IFNs, virus titers were reduced from 3.2–3.6 log."/>
  <result pre="a nebulizer (Snell, 2001). The proposed mechanisms of action of" exact="ribavirin" post="against viruses are indirect (inosine monophosphate dehydrogenase inhibition and"/>
  <result pre="2006). Shimojima et al. (2014) first reported the efficacy of" exact="ribavirin" post="in vitro using three cell lines: monkey kidney-derived Vero,"/>
  <result pre="hepatoma-derived Huh7, and human osteosarcoma-derived U2OS cells. When treated with" exact="ribavirin" post="before and during infection with SFTSV, the 99% inhibitory"/>
  <result pre="during infection with SFTSV, the 99% inhibitory concentration (IC99) of" exact="ribavirin" post="was 263, 83, and 78 μM in Vero, Huh7,"/>
  <result pre="respectively (Table 1). However, when Vero cells were treated with" exact="ribavirin" post="3 days after the inoculation, the inhibitory effect was"/>
  <result pre="the inoculation, the inhibitory effect was dramatically decreased, suggesting that" exact="ribavirin" post="could be used as post-exposure prophylaxis for the prevention"/>
  <result pre="prophylaxis for the prevention of SFTS and also mentioned that" exact="ribavirin" post="could be effective as part of a combination therapy"/>
  <result pre="treat SFTS patients (Shimojima et al., 2014). The efficacy of" exact="ribavirin" post="against SFTSV replication was also observed in another study,"/>
  <result pre="1). Despite several differences in viral strains and treatment procedure," exact="ribavirin" post="suppressed SFTS replication, suggesting that it was effective against"/>
  <result pre="Shimojima et al. (2015) investigated the improvement in efficacy when" exact="ribavirin" post="was used in combination with IFNs. All IFNs showed"/>
  <result pre="U/ml, 24 U/ml, and 12 ng/ml, respectively, and that of" exact="ribavirin" post="was 43 μg/mL (Table 1). When IFNs were combined"/>
  <result pre="was 43 μg/mL (Table 1). When IFNs were combined with" exact="ribavirin" post="at IC90, significant inhibitory effects were observed, with reductions"/>
  <result pre="in viral titers. This study suggested that the combination of" exact="ribavirin" post="with IFNs or other agents that function via different"/>
  <result pre="The Chinese Ministry of Health initially approved the use of" exact="ribavirin" post="to treat SFTS based on the results of in"/>
  <result pre="the case fatality rate was similar between patients who received" exact="ribavirin" post="and those who did not (Liu et al., 2013)."/>
  <result pre="311 patients, of whom 54 died; in those who received" exact="ribavirin" post="therapy, the platelet counts did not increase and the"/>
  <result pre="significant, it was unexpectedly observed that the patients who received" exact="ribavirin" post="therapy had lower platelet counts than those who did"/>
  <result pre="study reported that two patients, in whom plasma exchange and" exact="ribavirin" post="treatment were initiated early, recovered from rapidly progressing SFTS"/>
  <result pre="patients, the platelet counts began to gradually recover after initiating" exact="ribavirin" post="treatment. Furthermore, according to a large-scale epidemiological study in"/>
  <result pre="including 2096 patients with laboratory-confirmed SFTS between 2011 and 2017," exact="ribavirin" post="therapy was effective in reducing the case fatality rate"/>
  <result pre="cells (Tani et al., 2016) was lower than that of" exact="ribavirin" post="(263 μM) (Shimojima et al., 2014). The efficacy of"/>
  <result pre="On the other hand, ~40% of the mice treated with" exact="ribavirin" post="(i.p.) at a dose of 25 or 100 mg/kg/day"/>
  <result pre="aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them," exact="hexachlorophene" post="was the most potent, with an IC50 of 1.3"/>
  <result pre="antiviral drugs identified (Table 1). Furthermore, the results indicated that" exact="hexachlorophene" post="treatment interfered with SFTSV entry without affecting virus-host cell"/>
  <result pre="virus infectivity (Yuan et al., 2019). It was predicted that" exact="hexachlorophene" post="would bind to the deep hydrophobic pocket between domains"/>
  <result pre="cholinesterase inhibitor (Hsu et al., 2004). It was reported that" exact="hexachlorophene" post="inhibited the viral replication of severe acute respiratory syndrome-related"/>
  <result pre="of 700 FDA-approved drugs identified the CCBs benidipine hydrochloride and" exact="nifedipine" post="as inhibitors of SFTSV replication in vitro by impairing"/>
  <result pre="in vitro study suggested that treatment with benidipine hydrochloride or" exact="nifedipine" post="inhibited SFTSV replication by reducing virus induced Ca2+ influx."/>
  <result pre="and decreased fatality rate in the humanized mouse model. Notably," exact="nifedipine" post="is one of the most widely used drugs for"/>
  <result pre="of 2087 patients with SFTS comprising 83 nifedipine-treated, who received" exact="nifedipine" post="before admission and during hospitalization, 48 non-nifedipine-treated ones who"/>
  <result pre="before admission and during hospitalization, 48 non-nifedipine-treated ones who received" exact="nifedipine" post="before admission but not during hospitalization, and 249 general"/>
  <result pre="hospitalization, and 249 general SFTS patients who did not receive" exact="nifedipine" post="at all. The case fatality rate was decreased by"/>
  <result pre="authors clearly showed the inhibitory effect of benidipine hydrochloride or" exact="nifedipine" post="in cultured cells and an animal model. Most importantly,"/>
  <result pre="an animal model. Most importantly, it was found that the" exact="nifedipine" post="administration enhanced virus clearance and improved clinical recovery. 2′-Fluoro-2′-deoxycytidine"/>
  <result pre="(Table 1). This value was much lower than that of" exact="ribavirin" post="(49.7 μM) in the same study and favipiravir (22"/>
  <result pre="(Balasubramanian et al., 2017). The mechanism of inhibitory activity of" exact="amodiaquine" post="against malaria and those viruses remains unclear. Baba et"/>
  <result pre="remains unclear. Baba et al. (2017) investigated the effect of" exact="amodiaquine" post="and other halogen molecules (fluorine, bromine, and iodine) against"/>
  <result pre="bromine, and iodine, respectively (Table 1). Among the compounds tested," exact="amodiaquine" post="was identified as a selective inhibitor against SFTSV replication."/>
  <result pre="inhibitor against SFTSV replication. The CC50 and the IC50 of" exact="amodiaquine" post="was &amp;gt;100 and 19.1 μM, respectively. The IC50 of"/>
  <result pre="amodiaquine was &amp;gt;100 and 19.1 μM, respectively. The IC50 of" exact="amodiaquine" post="was lower than those of ribavirin (40.1 μM) and"/>
  <result pre="respectively. The IC50 of amodiaquine was lower than those of" exact="ribavirin" post="(40.1 μM) and favipiravir (25.0 μM). IFN-γ IFN-γ is"/>
  <result pre="China, 2011). The in vitro and in vivo studies on" exact="ribavirin" post="(Shimojima et al., 2014, 2015; Tani et al., 2016;"/>
  <result pre="study conducted by Liu et al. (2013), which showed that" exact="ribavirin" post="did not reduce the fatality rate of patients with"/>
  <result pre="fatality rate of patients with SFTS, discouraged us from considering" exact="ribavirin" post="treatment for treating patients with SFTS. However, Li et"/>
  <result pre="patients with SFTS. However, Li et al. (2018) reported that" exact="ribavirin" post="is effective for early-stage patients with a low viral"/>
  <result pre="for the pretreatment of exposed individuals. Nevertheless, in cases of" exact="ribavirin" post="administration, patients should be intensely monitored because of the"/>
  <result pre="intensely monitored because of the possible adverse events induced by" exact="ribavirin" post="such as anemia and hyperamylasemia (Lu et al., 2015)."/>
  <result pre="hyperamylasemia (Lu et al., 2015). Favipiravir exhibited higher effectiveness than" exact="ribavirin" post="in in vitro and in vivo studies (Tani et"/>
  <result pre="using an FDA-approved drug library (Yuan et al., 2019). Because" exact="hexachlorophene" post="can cause acute and subacute neurotoxicity in laboratory animals"/>
  <result pre="et al., 2019). Notably, retrospectively conducted clinical study suggested that" exact="nifedipine" post="remarkably reduced the case fatality rate in SFTS patients"/>
  <result pre="fatality rate in SFTS patients (Li et al., 2019). Although" exact="nifedipine" post="is administrated consistently for patients with cardiac disease, these"/>
  <result pre="therapeutics for SFTS. It is considered that the efficacy of" exact="nifedipine" post="in treating patients with SFTS should be evaluated in"/>
  <result pre="further studies are needed. Baba et al. (2017) showed that" exact="amodiaquine" post="and other halogen molecules effectively inhibited the propagation of"/>
  <result pre="can be administered at a low cost. The efficacy of" exact="amodiaquine" post="in vivo should be evaluated. The anti-SFTSV efficacy of"/>
  <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance. Curr. Opin. Virol.8, 10–15. 10.1016/j.coviro.2014.04.01124846716 BoonyasuppayakornS.ReichertE. D.ManzanoM.NagarajanK.PadmanabhanR. (2014)."/>
  <result pre="10.1093/jac/dku20924951535 DewaldL. E.DyallJ.SwordJ. M.TorzewskiL.ZhouH.PostnikovaE.et al. (2018). The calcium channel blocker" exact="bepridil" post="demonstrates efficacy in the murine model of marburg virus"/>
  <result pre="e01942–e01916. 10.1128/JVI.01942-1627881648 GraciJ. D.CameronC. E. (2006). Mechanisms of action of" exact="ribavirin" post="against distinct viruses. Rev. Med. Virol.16, 37–48. 10.1002/rmv.48316287208 HsuJ."/>
  <result pre="J.ChoeP. G.ParkW. B.et al.. (2017). In vitro antiviral activity of" exact="ribavirin" post="against severe fever with thrombocytopenia syndrome virus. Korean J."/>
  <result pre="LiuW.LuQ. B.CuiN.LiH.WangL. Y.LiuK.et al.. (2013). Case-fatality ratio and effectiveness of" exact="ribavirin" post="therapy among hospitalized patients in china who had severe"/>
  <result pre="G.FanY. D.GuoC. T.et al.. (2015). Common adverse events associated with" exact="ribavirin" post="therapy for Severe fever with thrombocytopenia syndrome. Antiviral Res.119,"/>
  <result pre="S.HeoS. T.KimS. H.ChoiW. J.HanM. G.KimJ. Y. (2014). Plasma exchange and" exact="ribavirin" post="for rapidly progressive severe fever with thrombocytopenia syndrome. Int."/>
  <result pre="(2016). Longitudinal diffusion tensor imaging of the rat brain after" exact="hexachlorophene" post="exposure. Neurotoxicology56, 225–232. 10.1016/j.neuro.2016.08.01127555423 SaijoM. (2018). Pathophysiology of severe"/>
  <result pre="disease treatment. Science. 347, 995–998. 10.1126/science.125875825722412 SakuraiY.SakakibaraN.ToyamaM.BabaM.DaveyR. A. (2018). Novel" exact="amodiaquine" post="derivatives potently inhibit Ebola virus infection. Antiviral Res.160, 175–182."/>
  <result pre="virus infection. Virology482, 19–27. 10.1016/j.virol.2015.03.01025817401 ShimojimaM.FukushiS.TaniH.TaniguchiS.FukumaA.SaijoM. (2015). Combination effects of" exact="ribavirin" post="and interferons on severe fever with thrombocytopenia syndrome virus"/>
  <result pre="virus infection. Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects of" exact="ribavirin" post="on severe fever with thrombocytopenia syndrome virus in vitro."/>
 </snippets>
</snippetsTree>
